SAMPA PAL

Dr. SAMPA PAL


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2018 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
SPSAMPA PAL
SAMPA PAL
PBPooja Bansil
Pooja Bansil
GBGermana Bancone
Germana Bancone
SHSevan Hrutkay
Sevan Hrutkay
MKMaria Kahn
Maria Kahn
GDGonzalo Domingo
Gonzalo Domingo
Glucose-6-phosphate dehydrogenase (G6PD) deficiency, a common genetic blood condition, can result in kernicterus at birth, and later in life as severe hemolysis on exposure to certain infections, foods, and drugs. The unavailability of point-of-care tests for G6PD deficiency is a barrier to routine curative treatment of Plasmodium vivax malaria with 8-aminoquinolines, such as primaquine. Two quantitative reference tests (Trinity Biotech, Bray, Ireland and Pointe Scientific, Canton, MI; Cat No. G7583) and the point-of-care STANDARD™ G6PD test (SD Biosensor, Suwon, South Korea) were evaluated. The STANDARD G6PD test was evaluated at multiple temperatures, in anticoagulated venous and capillary samples, including 79 G6PD-deficient and 66 intermediate samples and across two laboratories, one in the United States and one in Thailand. The STANDARD test performed equivalently to a reference assay for its ability to diagnose G6PD deficiency (< 30% normal) with a sensitivity of 100% (0.95 confidence interval [CI]: 95.7–100) and specificity of 97% (0.95 CI: 94.5–98.5), and could reliably identify females with less than 70% normal G6PD activity with a sensitivity of 95.5% (0.95 CI: 89.7–98.5) and specificity of 97% (0.95 CI: 94.5–98.6). The STANDARD G6PD product represents an opportunity to diagnose G6PD deficiency equally for males and females in basic clinical laboratories in high- and low-resource settings. This quantitative point-of-care diagnostic test for G6PD deficiency can provide equal access to safe radical cure of P. vivax cases in high- and low-resource settings, for males and females and may support malaria elimination, in countries where P. vivax is endemic.

Verified
Journal Article
Open access
PDF file
AAAthena Anderle
Athena Anderle
GBGermana Bancone
Germana Bancone
GDGonzalo Domingo
Gonzalo Domingo
EGEmily Gerth-Guyette
Emily Gerth-Guyette
SPSAMPA PAL
SAMPA PAL
ASAri W. Satyagraha
Ari W. Satyagraha
Glucose-6-phosphate dehydrogenase (G6PD) deficiency, an X-linked genetic disorder, is associated with increased risk of jaundice and kernicterus at birth. G6PD deficiency can manifest later in life as severe hemolysis, when the individual is exposed to oxidative agents that range from foods such as fava beans, to diseases such as typhoid, to medications such as dapsone, to the curative drugs for Plasmodium (P.) vivax malaria, primaquine and tafenoquine. While routine testing at birth for G6PD deficiency is recommended by the World Health Organization for populations with greater than 5% prevalence of G6PD deficiency and to inform P. vivax case management using primaquine, testing coverage is extremely low. Test coverage is low due to the need to prioritize newborn interventions and the complexity of currently available G6PD tests, especially those used to inform malaria case management. More affordable, accurate, point-of-care (POC) tests for G6PD deficiency are emerging that create an opportunity to extend testing to populations that do not have access to high throughput screening services. Some of these tests are quantitative, which provides an opportunity to address the gender disparity created by the currently available POC qualitative tests that misclassify females with intermediate G6PD activity as normal. In populations where the epidemiology for G6PD deficiency and P. vivax overlap, screening for G6PD deficiency at birth to inform care of the newborn can also be used to inform malaria case management over their lifetime.

14 September 2022 in Pathogens
Verified
Journal Article
Open access
PDF file
DPDaniel A. Pfeffer
Daniel A. Pfeffer
ASAri Winasti Satyagraha
Ari Winasti Satyagraha
ASArkasha Sadhewa
Arkasha Sadhewa
SAShafiul Alam
Shafiul Alam
GBGermana Bancone
Germana Bancone
Benedikt LeyBenedikt Ley
Benedikt Ley
Low glucose-6-phosphate dehydrogenase enzyme (G6PD) activity is a key determinant of drug-induced haemolysis. More than 230 clinically relevant genetic variants have been described. We investigated the variation in G6PD activity within and between different genetic variants. In this systematic review, individual patient data from studies reporting G6PD activity measured by spectrophotometry and corresponding the G6PD genotype were pooled (PROSPERO: CRD42020207448). G6PD activity was converted into percent normal activity applying study-specific definitions of 100%. In total, 4320 individuals from 17 studies across 10 countries were included, where 1738 (40.2%) had one of the 24 confirmed G6PD mutations, and 61 observations (3.5%) were identified as outliers. The median activity of the hemi-/homozygotes with A-(c.202G>A/c.376A>G) was 29.0% (range: 1.7% to 76.6%), 10.2% (range: 0.0% to 32.5%) for Mahidol, 16.9% (range 3.3% to 21.3%) for Mediterranean, 9.0% (range: 2.9% to 23.2%) for Vanua Lava, and 7.5% (range: 0.0% to 18.3%) for Viangchan. The median activity in heterozygotes was 72.1% (range: 16.4% to 127.1%) for A-(c.202G>A/c.376A>G), 54.5% (range: 0.0% to 112.8%) for Mahidol, 37.9% (range: 20.7% to 80.5%) for Mediterranean, 53.8% (range: 10.9% to 82.5%) for Vanua Lava, and 52.3% (range: 4.8% to 78.6%) for Viangchan. A total of 99.5% of hemi/homozygotes with the Mahidol mutation and 100% of those with the Mediterranean, Vanua Lava, and Viangchan mutations had A/c.376A>G), 55% of hemi/homozygotes had <30% activity. The G6PD activity for each variant spanned the current classification thresholds used to define clinically relevant categories of enzymatic deficiency.

8 June 2017 in Malaria Journal
Verified
Journal Article
Open access
PDF file
WYWoyneshet G. Yalew
Woyneshet G. Yalew
SPSAMPA PAL
SAMPA PAL
PBPooja Bansil
Pooja Bansil
RDRebecca Dabbs
Rebecca Dabbs
KTKevin Tetteh
Kevin Tetteh
RSRichard W. Steketee
Richard W. Steketee
Since 2005, Ethiopia has aggressively scaled up malaria prevention and case management. As a result, the number of malaria cases and deaths has significantly declined. In order to track progress towards the elimination of malaria in Amhara Region, coverage of malaria control tools and current malaria transmission need to be documented. A cross-sectional household survey oversampling children under 5 years of age was conducted during the dry season in 2013. A bivalent rapid diagnostic test (RDT) detecting both Plasmodium falciparum and Plasmodium vivax and serology assays using merozoite antigens from both these species were used to assess the prevalence of malaria infections and exposure to malaria parasites in 16 woredas (districts) in Amhara Region. 7878 participants were included, with a mean age of 16.8 years (range 0.5–102.8 years) and 42.0% being children under 5 years of age. The age-adjusted RDT-positivity for P. falciparum and P. vivax infection was 1.5 and 0.4%, respectively, of which 0.05% presented as co-infections. Overall age-adjusted seroprevalence was 30.0% for P. falciparum, 21.8% for P. vivax, and seroprevalence for any malaria species was 39.4%. The prevalence of RDT-positive infections varied by woreda, ranging from 0.0 to 8.3% and by altitude with rates of 3.2, 0.7, and 0.4% at under 2000, 2000–2500, and >2500 m, respectively. Serological analysis showed heterogeneity in transmission intensity by area and altitude and evidence for a change in the force of infection in the mid-2000s. Current and historic malaria transmission across Amhara Region show substantial variation by age and altitude with some settings showing very low or near-zero transmission. Plasmodium vivax infections appear to be lower but relatively more stable across geography and altitude, while P. falciparum is the dominant infection in the higher transmission, low-altitude areas. Age-dependent seroprevalence analyses indicates a drop in transmission occurred in the mid-2000s, coinciding with malaria control scale-up efforts. As malaria parasitaemia rates get very low with elimination efforts, serological evaluation may help track progress to elimination.

6 August 2020 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
SCSandra Chishimba
Sandra Chishimba
MMMulenga Mwenda
Mulenga Mwenda
BMBrenda Mambwe
Brenda Mambwe
CMConceptor Mulube
Conceptor Mulube
VCVictor Chalwe
Victor Chalwe
DBDaniel J. Bridges
Daniel J. Bridges
Malaria burden in Zambia has significantly declined over the last decade because of improved coverage of several key malaria interventions (e.g., vector control, case management, bed net distributions, and enhanced surveillance/responses). Campaign-based mass drug administration (MDA) and focal MDA (fMDA) were assessed in a trial in Southern Province, Zambia, to identify its utility in elimination efforts. As part of the study, a longitudinal cohort was visited and tested (by PCR targeting the 18s rRNA and a Plasmodium falciparum–specific rapid diagnostic test [RDT] from SD Bioline) every month for the trial duration (18 months). Overall, there was high concordance (> 97%) between the PCR and RDT results, using the PCR as the gold standard. The RDTs had high specificity and negative predictive values (98.5% and 98.6%, respectively) but low sensitivity (53.0%) and a low positive predictive value (53.8%). There was evidence for persistent antigenemia affecting the low specificity of the RDT, while false-negative RDTs were associated with a lower parasite density than true positive RDTs. Plasmodium falciparum was the dominant species identified, with 98.3% of all positive samples containing P. falciparum. Of these, 97.5% were mono-infections and 0.8% coinfections with one other species. Plasmodium malariae was found in 1.4% of all positive samples (50% mono-infections and 50% coinfections with P. falciparum), whereas Plasmodium ovale was found in 1.1% of all positive samples (90% mono-infections and 10% coinfections with P. falciparum). Although MDA/fMDA appeared to reduce P. malariae prevalence, P. ovale prevalence appeared unchanged.

4 April 2025 in medRxiv
Verified
Preprint
Open access
PDF file
ATArunansu Talukdar
Arunansu Talukdar
SDSantasabuj Das
Santasabuj Das
SMSandip Mukherjee
Sandip Mukherjee
SSSupriya Sharma
Supriya Sharma
NANaseem Ahmed
Naseem Ahmed
SPSAMPA PAL
SAMPA PAL
Background and objective: G6PD enzyme deficiency is a genetic condition that can lead to acute hemolysis. This study evaluates the clinical performance of the point-of-care STANDARD™ G6PD Test in Kolkata, India, an area of high incidence of urban vivax malaria. Methods: Evaluation of the STANDARD G6PD Test was performed against a reference G6PD assay using UV-spectrophotometry in a febrile population (N=951) recruited from outpatient clinics. Hemoglobin performance was compared to automated hematology analyzer measurements from venous blood. Genotyping was performed on a subset of samples including all deficients/intermediates to identify variants. Results: G6PD deficiency was 2.8%. 20.4% of the study population and had either moderate or severe anemia at enrollment. The test’s sensitivity and specificity were 100% (95% CI: 87.2%– 100%) and 97.8% (96.3%–98.8%), respectively, for G6PD deficient cases. Sensitivity and specificity for females with intermediate G6PD activity were 62.5 % (35.4%–84.8%) and 96.1% (93.3%–98.0%), respectively. Female intermediates with false normal G6PD results had reference G6PD activity greater than 45%. Among malaria-positive individuals (N=272), the test showed 100% sensitivity for both deficient and intermediate G6PD cases. Fifteen participants were identified as Orissa, 1 as Mahidol and 2 as Mediterranean variants. All severe anemia cases (n=24) were accurately categorized as such by STANDARD G6PD test. Interpretation and conclusion: The STANDARD G6PD Test tested at the fever clinic setting was reliable in diagnosing patients at greatest risk of drug induced hemolysis and supports safe treatment of P. vivax in this population.